NASDAQ
12.38USD
+0.31 (+2.57%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
707.8M
P/E
—
EPS
—
Beta
0.23
52W range
10.52-34.475
Day range
11.82–12.51
Open
12.27
Prev close
12.07
Volume
257.3K
Avg volume
693K
Dividend
0.00
IPO
2021-05-18
https://www.zacks.com/stock/news/2970647/oculis-holding-ag-ocs-reports-q2-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2970647 · 8/7/2026+0.40
https://www.globenewswire.com/news-release/2026/07/02/3321125/0/en/Oculis-to-Participate-at-the-Piper-Sandler-Virtual-Ophthalmology-Conference.html · 7/2/2026+0.60
https://www.globenewswire.com/news-release/2026/06/23/3316525/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Oculis-Holding-AG-OCS.html · 6/23/2026-1.00
https://www.globenewswire.com/news-release/2026/06/17/3313555/0/en/OCS-Investors-Have-Opportunity-to-Join-Oculis-Holding-AG-Fraud-Investigation-with-the-Schall-Law-Firm.html · 6/17/2026-1.00
https://www.globenewswire.com/news-release/2026/06/16/3313058/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-Erasca-Inc-of-Class-Action-Lawsuit-and-Upcoming-Deadlines-ERAS.html · 6/16/2026-0.50
https://www.newsfilecorp.com/release/300878/Potential-Securities-Fraud-Levi-Korsinsky-Investigates-The-Ensign-Group-Inc.-ENSG · 6/10/2026-1.00
https://www.newsfilecorp.com/release/300484/Lost-Money-on-Shake-Shack-Inc.-SHAK-Contact-Levi-Korsinsky-to-Protect-Your-Rights · 6/8/2026-0.50
https://www.prnewswire.com/news-releases/abivax-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-abivax-abvx-302789317.html · 6/3/2026-0.80
https://www.prnewswire.com/news-releases/oculis-holding-ag-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-oculis-holding-ag-ocs-302787489.html · 6/1/2026-1.00
https://www.globenewswire.com/news-release/2026/05/05/3287391/0/en/latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting.html · 5/5/2026+0.80
https://www.globenewswire.com/news-release/2026/04/20/3276737/0/en/Oculis-Announces-Completion-of-Last-Patient-Visit-in-Phase-3-DIAMOND-Program-with-OCS-01-Eye-Drops-for-the-Treatment-of-Diabetic-Macular-Edema.html · 4/20/2026+0.80
https://www.globenewswire.com/news-release/2026/04/20/3276735/0/en/Oculis-Announces-Completion-of-Last-Patient-Visit-in-Phase-3-DIAMOND-Program-with-OCS-01-Eye-Drops-for-the-Treatment-of-Diabetic-Macular-Edema.html · 4/20/2026+0.80
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
